Manufacturing

July 8, 2026 Scaling Responsibly: Alnylam’s Approach to Sustainable Operations Growth expands our ability to serve patients. It also expands our responsibility for how that work is done. Modern medicines require energy, water, materials, transportation Read More ›
March 26, 2026 Alnylam Awarded 2026 Scientific Impact Award by MassBio Alnylam was recognized by Mass Bio for its pioneering work in RNA interference and the development of RNAi therapeutics as an innovative new class of medicines. Read More ›
December 17, 2025 Alnylam Announces Major Expansion of U.S. Pharmaceutical Manufacturing Facility $250 million investment will add new capacity and siRNA enzymatic ligation capabilities to Alnylam's Norton, Massachusetts site Read More ›
September 30, 2025 How Alnylam’s Manufacturing Investments Bring RNAi Therapeutics to More Patients, Faster Translating our pioneering work in RNAi not only requires innovation in the lab - it requires innovation in how we make our medicines. Read More ›
December 4, 2023 Being a Steward of the Planet in an Energy-Intensive Industry Learn about how Alnylam is sourcing renewable energy for energy-intensive operations including manufacturing Read More ›
February 4, 2022 Alnylam Receives Prestigious Massachusetts Economic Impact Award We are pleased and honored to have been named a Gold Team Massachusetts Economic Impact Award winner for 2022 by MassEcon. Read More ›
October 1, 2019 The Importance of Ensuring Quality in a New Class of Medicines In Product Quality, we have a truly big picture view of the medicines we’re making to ensure they are compliant with good manufacturing practices and... Read More ›
October 1, 2019 Building for Our Future Why would a company without a commercially approved medicine decide to build a significant manufacturing facility? Why not continue to rely on contract... Read More ›
Subscribe to Manufacturing